Human Anti-CTLA4 Recombinant Antibody (HPAB-M0042-YC)

Customer Review

There are currently no Customer reviews or questions for HPAB-M0042-YC. Click the button above to contact us or submit your feedback about this product.

Citations

1. Wiese, Teresa. Pharmacological targeting of acid sphingomyelinase increases CD4\(^+\) Foxp3\(^+\) regulatory T cell subsets in patients with major depression. Diss. Universität Würzburg, 2022. https://doi.org/10.25972/OPUS-23347
   This research investigates the effects of acid sphingomyelinase (ASM) inhibition on regulatory T cell (Treg) populations in humans. The study demonstrates that pharmacological inhibition of ASM, particularly through antidepressants with strong ASM-inhibitory capacity, leads to increased frequencies of effector regulatory T cells (efTregs) among CD4+ T cells both in vitro and in patients treated for major depression. The researchers found that ASM inhibition enhances CD28 co-stimulation in Tregs, promoting their survival without affecting their suppressive function. Additionally, the study identified an early increase in efTreg frequencies as a potential biomarker for positive clinical response to antidepressant treatment, independent of the drug's ASM-inhibitory capacity. These findings suggest that ASM inhibition could be therapeutically beneficial for autoimmune diseases characterized by reduced Treg frequencies.
   Creative Biolabs provided the CTLA-4 inhibiting monoclonal antibody tremelimumab and the PD-1 inhibiting monoclonal antibody pembrolizumab, which were crucial for understanding the mechanistic relationship between immune checkpoint inhibition and ASM activity. These antibodies allowed the researchers to demonstrate that both ASM inhibition and CTLA-4 blockade increase efTreg frequencies through a common CD28-dependent pathway, providing key insights into how ASM modulates T cell homeostasis and identifying potential therapeutic targets for inflammatory and autoimmune conditions.

Submit Your Publication

Published with our product? Submit your paper and receive a 10% discount on your next order! Share your research to earn exclusive rewards.

Related Diseases

Downloadable Resources

Download resources about recombinant antibody development and antibody engineering to boost your research.

Product Notes

This is a product of Creative Biolabs' Hi-Affi™ recombinant antibody portfolio, which has several benefits including:

• Increased sensitivity
• Confirmed specificity
• High repeatability
• Excellent batch-to-batch consistency
• Sustainable supply
• Animal-free production

See more details about Hi-Affi™ recombinant antibody benefits.

Datasheet

MSDS

COA

Certificate of Analysis Lookup

To download a Certificate of Analysis, please enter a lot number in the search box below. Note: Certificate of Analysis not available for kit components.

See other products for "CTLA4"

Select a product category from the dropdown menu below to view related products.

Human Antibodies Immunotoxins Rat Antibodies Chimeric Antibodies Mouse Antibodies Humanized Antibodies Neutralizing Antibodies Blocking Antibodies Rabbit Monoclonal Antibodies IgG Antibodies ScFv Antibodies Fab Antibodies ADCC Enhanced Antibodies Single Domain Antibodies Agonistic Antibodies Antibody Magnetic Beads FC Reagents & Kits ScFv-Fc Chimeras Extracellular Vesicle Antibodies IHC Kits & Antibodies